fusion

TAT-NSF222 Fusion Peptide is a bifunctional polypeptide comprising a TAT domain, facilitating cellular uptake via macropinocytosis, and an NSF domain, which acts as an inhibitor of N-ethylmaleimide-sensitive factor (NSF). This fusion peptide serves as an exocytosis inhibitor [1].

TAT-HA2 Fusion Peptide, a peptide-based delivery agent, synergizes the pH-sensitive HA2 fusion peptide from Influenza with the cell-penetrating peptide TAT from HIV. This compound facilitates the cellular uptake of macromolecules through the TAT component and triggers their release into cells by exploiting the acidifying endosomal lumen to induce membrane leakage via the HA2 component [1].

TAT-NSF700 Fusion Peptide, a potent inhibitor of N-ethyl-maleimide-sensitive factor (NSF), possesses the ability to penetrate cell membranes and directly interact with intracellular organelles [1].

FN-A208 is an active peptide combining A208 from murine laminin a1 with the fibronectin active site GRGDS, linked by a glycine spacer. This compound self-assembles into amyloid-like fibrils and facilitates fibroblast cell adhesion through actin stress fiber formation, suggesting its use as a bioadhesive in tissue regeneration and engineering. FN-A208 targets IKVAV receptors and integrins, but its function can be inhibited by EDTA.

Fusion glycoprotein (92-106) [Human respiratory syncytial virus] is a peptide with the sequence H2N-Glu-Leu-Gln-Leu-Leu-Met-Gln-Ser-Thr-Pro-Pro-Thr-Asn-Asn-Arg-OH, MW= 1741.96.

TAT-GluR23A Fusion Peptide is a bioactive peptide comprising the GluR23A sequence—residues 869 to 877 of GluR23Y with alanine replacing tyrosine—and an 11 amino acid cell-permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). It serves as an inactive control counterpart to the glutamate receptor endocytosis inhibitor GluR23Y, devoid of crucial phosphorylation sites.

TAT-NSF700 Fusion Peptide acetate is a membrane-permeable inhibitor of N-ethyl-maleimide-sensitive factor (NSF), a fusion peptide with potential anti-inflammatory activity.TAT-NSF700 Fusion Peptide acetate interacts with intracellular organelles and can be used to investigate Myocardial ischemia and reperfusion injury.

Leupeptin hemisulfate is a protease inhibitor with cell membrane-permeable, reversible, competitive, and oral activities. Leupeptin hemisulfate inhibits the activity of Cathepsin B, Cathepsin H, and Cathepsin L, and blocks fusion of amphipathic lysosomes. Leupeptin hemisulfate also has anti-inflammatory activity.

740 Y-P acetate (740YPDGFR acetate) is a potent and cell-permeable PI3K activator.740 Y-P acetate tends to bind to GST fusion proteins containing the N- and C-terminal SH2 structural domains of p85, but not to GST alone.

Crosstide is a peptide analog of glycogen synthase kinase α/β fusion protein sequence which is a substrate for Akt.

Pep2m, myristoylated acetate is a Cell-permeable, myristoylated form of pep2m. Peptide inhibitor of the interaction between the C-terminus of the GluA2 (AMPA receptor) subunit and N-ethylmaleimide-sensitive fusion protein (NSF), a protein that regulates A

pep2m aceate is a Peptide inhibitor of the interaction between the C-terminus of the GluR2 subunit and N-ethylmaleimide-sensitive fusion protein

TRV120056 acetate is a Gq-biased agonist with 10-fold greater molecular efficiency on AT1R-Gq fusion proteins than AT1R-βarr2 fusion proteins.

Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connected through a 101 GGSGGSGGSGGSGGS 115 peptide linker to the N-terminus (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain with L352>A and L353>A mutations. Additionally, sotiburafusp alfa functions as an angiogenesis inhibitor [1].

c-Myc Peptide is a useful displacement of c-Myc-tagged fusion proteins bound to anti-c-Myc antibodies in immunoassays. The successful inhibition of antibody binding by c-Myc peptide demonstrates binding is specific. c-Myc peptide participates in the regul

Siamycin I is a tricyclic peptide originally isolated from Streptomyces and has antiviral and antibacterial activities. It is active against laboratory strains and clinical isolates of HIV-1 (ED50s = 0.05-0.45 and 0.89-5.7 μM, respectively), as well as the CBL-20 strain of HIV-2 (ED50 = 0.45 μM), in vitro. Siamycin I inhibits HIV-induced fusion of C8166 T cells with HIV-1-infected CEM-SS cells with an ED50 value of 0.08 μM. It is also active against B. subtilis, M. luteus, and S. aureus (MICs = 1.6-6.3 μg/ml). Siamycin I inhibits autophosphorylation of the E. faecalis quorum sensing kinase FsrC induced by gelatinase biosynthesis-activating pheromone (GBAP).

β-Amyloid (29-40) is a fragment of Amyloid-β peptide.Alzheimer's beta amyloid peptide (29-40/42) C-terminal fragments have physical and chemical properties related to those of fusion peptides of viral proteins. The fusion of liposomes can be induced by th

Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extracellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). It is a selective T-cell co-stimulation modulator and a protein drug for au

GluR23Y, a biologically active peptide, was utilized in an ELISA-based cell-surface assay to assess insulin-stimulated endocytosis of native AMPA receptors in cultured hippocampal neurons. GluR23Y effectively inhibited the insulin-induced decrease in receptor presence. The inhibition of insulin effects was achieved by introducing GluR23Y into neurons through fusion with the membrane transduction domain of HIV-1 TAT.

N36 peptide, an (HIV-1 gp41 fusion peptide), exhibits biological activity.

Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection.

Cell-permeable, myristoylated form of pep2m. Peptide inhibitor of the interaction between the C-terminus of the GluA2 (AMPA receptor) subunit and N-ethylmaleimide-sensitive fusion protein (NSF), a protein that regulates AMPA receptor function. Reduces pos

Tat-peptide 190-208 TFA is a Tat-labeled, cell-permeable fusion peptide derived from residues 190-208 of rat G3BP1. The HIV-derived Tat sequence, positioned at the peptide's least conserved region, confers cellular permeability. This compound promotes axon growth and enhances the formation of neurites per neuron, suggesting an axon intrinsic mechanism of action. Additionally, it has potential applications in providing ischemic protection during endovascular repair of intracranial aneurysms [1].

Tat-peptide 168-189, a cell-permeable, Tat-labeled fusion peptide derived from residues 168-189 of rat G3BP1, features the HIV Tat sequence at its least conserved terminus to enhance cellular uptake. It serves as the negative control for Tat-peptide 168-189 TFA, which promotes axon growth and neurite proliferation [1].

Tifuvirtide (T-1249) is a synthetically designed peptide and a fusion inhibitor targeting human immunodeficiency virus type-1 (HIV-1), exhibiting antiretroviral activity. This hybrid retroviral envelope polypeptide is utilized in the research of HIV infection [1].

EGFRvIII peptide, a synthetic peptide mirroring the EGFRvIII fusion junction—a tumor-specific, perpetually active EGFR variant missing amino acids 6-273 of the wild-type—binds to HLA-A*0201-positive T2 cells under MHC class I at 25 µg/ml. It enables antigen presentation in dendritic cells from human peripheral blood mononuclear cells (PBMCs), thus activating CD8+ cytotoxic T lymphocytes and prompting IFN-γ production. Administered at 15 µg/animal with the TLR5 agonist flagellin B, EGFRvIII peptide elevates CD8+ T cell numbers, lowers regulatory T cells (Tregs) in the brain, diminishes tumor volume, and extends survival in a GL261 glioblastoma mouse model.

SARS-CoV-2-IN-34 (S-20-1) is a broad-spectrum pan-coronavirus (CoV) fusion inhibitor capable of penetrating the blood-brain barrier and demonstrating extensive inhibitory activity against both pseudotyped and authentic SARS-CoV-2, as well as pseudotyped variants of concern (VOCs). It exhibits high affinity for the receptor-binding domain (RBD) in the S1 and the heptad repeat 1 (HR1) domain in the S2 of the SARS-CoV-2 spike (S) protein, making it a valuable tool for infection research [1].

Phenylalanylalanine (H-Phe-Ala-OH) (H-Phe-Ala-OH) is a dipeptide resulting from the fusion of phenylalanine and alanine. It is formed during incomplete protein digestion or catabolism [1].

TRV120055, a Gq-biased agonist, demonstrates a 10-fold higher molecular efficacy when tested against the AT1R-Gq fusion protein in comparison to the AT1R-βarr2 fusion protein.

740 Y-P TFA, a potent, cell-permeable PI3K activator, exhibits selective binding affinity for GST fusion proteins encompassing the N- and C-terminal SH2 domains of p85, yet does not interact with GST in isolation [1].

The DYKDDDDK-tag system utilizes a short, hydrophilic 8- amino-acid peptide that is fused to the protein of interest1. The DYKDDDDK peptide binds to the antibody M1. To improve the detection of the DYKDDDDK tag the 3x (DYKDDDDK) system has been developed.

TRV120056 is a Gq-biased agonist that demonstrates a molecular efficacy ten times greater at the AT1R-Gq fusion protein than at the AT1R-βarr2 fusion protein.

C34 peptide, also referred to as HR2, is a biologically active peptide integral to the helical region of HIV's gp41 and is specifically the C-terminal heptad repeat 2 (HR2), denoted as the C helix or C peptide. It functions as a potent inhibitor of HIV-1 fusion, thereby impeding the virus's entry into cells via membrane fusion.

MPG, a 27-amino acid peptide compound, is derived from the fusion peptide domain of HIV-1 gp41 and the nuclear localisation sequence of SV40 large T antigen. As a potent delivery agent, MPG enables efficient and widespread transport of nucleic acids and oligonucleotides into cultured cells.